Zacks: Analysts Expect Nautilus Biotechnology, Inc. (NASDAQ:NAUT) to Post -$0.17 EPS

Analysts expect Nautilus Biotechnology, Inc. (NASDAQ:NAUTGet Rating) to post ($0.17) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Nautilus Biotechnology’s earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.15). Nautilus Biotechnology reported earnings of ($0.19) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.5%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Nautilus Biotechnology.

Nautilus Biotechnology (NASDAQ:NAUTGet Rating) last released its quarterly earnings results on Thursday, February 24th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02.

A number of research firms recently weighed in on NAUT. The Goldman Sachs Group dropped their price target on shares of Nautilus Biotechnology from $9.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 13th. Zacks Investment Research lowered shares of Nautilus Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, April 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Hold” and an average target price of $8.67.

NAUT opened at $3.85 on Wednesday. The company’s 50-day moving average is $4.12 and its 200 day moving average is $4.46. Nautilus Biotechnology has a fifty-two week low of $3.13 and a fifty-two week high of $12.38. The firm has a market capitalization of $479.18 million and a P/E ratio of -6.75.

In related news, CEO Sujal M. Patel acquired 50,000 shares of the stock in a transaction on Monday, May 9th. The shares were acquired at an average price of $3.96 per share, with a total value of $198,000.00. Following the completion of the transaction, the chief executive officer now owns 9,964,488 shares in the company, valued at approximately $39,459,372.48. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James & Associates increased its stake in shares of Nautilus Biotechnology by 18.0% in the third quarter. Raymond James & Associates now owns 18,797 shares of the company’s stock worth $115,000 after purchasing an additional 2,863 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Nautilus Biotechnology by 35.1% in the first quarter. JPMorgan Chase & Co. now owns 14,783 shares of the company’s stock worth $64,000 after purchasing an additional 3,837 shares in the last quarter. Citigroup Inc. increased its stake in shares of Nautilus Biotechnology by 130.3% in the first quarter. Citigroup Inc. now owns 10,387 shares of the company’s stock worth $45,000 after purchasing an additional 5,877 shares in the last quarter. State Street Corp increased its stake in shares of Nautilus Biotechnology by 4.9% in the first quarter. State Street Corp now owns 185,955 shares of the company’s stock worth $807,000 after purchasing an additional 8,755 shares in the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in shares of Nautilus Biotechnology by 67.5% in the fourth quarter. Qube Research & Technologies Ltd now owns 25,166 shares of the company’s stock worth $130,000 after purchasing an additional 10,138 shares in the last quarter. Hedge funds and other institutional investors own 47.89% of the company’s stock.

Nautilus Biotechnology Company Profile (Get Rating)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

Featured Stories

Get a free copy of the Zacks research report on Nautilus Biotechnology (NAUT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nautilus Biotechnology (NASDAQ:NAUT)

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.